3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
20
CRVO Quote, Financials, Valuation and Earnings
Last price:
$2.32
Seasonality move
:
24.68%
Day range:
$2.21 - $2.37
52-week range:
$1.80 - $26.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.47x
P/B ratio:
0.42x
Volume:
385.2K
Avg. volume:
778.8K
1-year change:
-75.11%
Market cap:
$19.3M
Revenue:
--
EPS (TTM):
-$1.65
Analysts' Opinion
-
Consensus RatingCervoMed has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 5 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $20.00, CervoMed has an estimated upside of 754.7% from its current price of $2.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $2.34.
Fair Value
-
According to the consensus of 7 analysts, CervoMed has 754.7% upside to fair value with a price target of $20.00 per share.
CRVO vs. S&P 500
-
Over the past 5 trading days, CervoMed has underperformed the S&P 500 by -4.03% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CervoMed does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CervoMed revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter CervoMed reported revenues of --.
Earnings Growth
-
CervoMed has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CervoMed reported earnings per share of -$0.55.
Enterprise value:
-27.3M
EV / Invested capital:
--
Price / LTM sales:
23.47x
EV / EBIT:
--
EV / Revenue:
-40.66x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
2.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$13.2M | -$6.3M | -$13.5M | -$2.7M | -$5.4M | |
| EBITDA | -$13.1M | -$8.6M | -$7.8M | -$2.7M | -$5.4M | |
| Diluted EPS | -$10.55 | -$7.43 | -$1.65 | -$0.70 | -$0.55 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.7M | $40.7M | $26.3M | $11.8M | $48.8M | |
| Total Assets | $31.9M | $40.9M | $26.3M | $12M | $48.9M | |
| Current Liabilities | $2.7M | $2.7M | $2.3M | $2.5M | $3.2M | |
| Total Liabilities | $3.2M | $2.7M | $2.3M | $2.5M | $3.2M | |
| Total Equity | $28.7M | $38.1M | $24.1M | $9.6M | $45.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.9M | -$5.6M | -$11M | -$1.5M | -$4.9M | |
| Cash From Investing | $4K | -- | -- | -- | $2.6M | |
| Cash From Financing | -- | -- | -- | $11.2M | -$13.3K | |
| Free Cash Flow | -$4.9M | -$5.6M | -$11M | -$1.5M | -$4.9M | |
CRVO
Sector
Market Cap
$19.3M
$49.2M
Price % of 52-Week High
8.87%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-75.11%
-30.94%
Beta (5-Year)
1.782
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.33
200-day SMA
Sell
Level
$15.70
Bollinger Bands (100)
Sell
Level
6.65 - 16.67
Chaikin Money Flow
Sell
Level
-245.4M
20-day SMA
Sell
Level
$3.07
Relative Strength Index (RSI14)
Sell
Level
28.65
ADX Line
Buy
Level
39.5
Williams %R
Neutral
Level
-23.9437
50-day SMA
Sell
Level
$8.01
MACD (12, 26)
Sell
Level
-1.72
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
140.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Stock Forecast FAQ
In the current month, CRVO has received 1 Buy ratings 5 Hold ratings, and 1 Sell ratings. The CRVO average analyst price target in the past 3 months is $20.00.
-
Where Will CervoMed Stock Be In 1 Year?
According to analysts, the consensus estimate is that CervoMed share price will rise to $20.00 per share over the next 12 months.
-
What Do Analysts Say About CervoMed?
Analysts are divided on their view about CervoMed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CervoMed is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is CervoMed's Price Target?
The price target for CervoMed over the next 1-year time period is forecast to be $20.00 according to 7 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is CRVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CervoMed is a Hold. 5 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CRVO?
You can purchase shares of CervoMed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CervoMed shares.
-
What Is The CervoMed Share Price Today?
CervoMed was last trading at $2.32 per share. This represents the most recent stock quote for CervoMed. Yesterday, CervoMed closed at $2.34 per share.
-
How To Buy CervoMed Stock Online?
In order to purchase CervoMed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
26
NARI alert for Jan 7
Inari Medical [NARI] is up 30.64% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is up 22.41% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 18.99% over the past day.
